- Conditions
- Carcinoid Syndrome
- Interventions
- Xermelo
- Drug
- Lead sponsor
- TerSera Therapeutics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 223 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Research Triangle Park, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Kidney Transplant; Complications, Toxicity, Drug Toxicity, Neurotoxicity
- Interventions
- Envarsus, IR Tacrolimus
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Cardiac Toxicity, Malignant Neoplasm, Breast Cancer
- Interventions
- Magnetic resonance imaging, Physical Activity, Healthy Living, Cardiopulmonary Exercise Testing (CPET), Questionnaire Administration
- Procedure · Other · Device
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 2
- States / cities
- Winston-Salem, North Carolina • Richmond, Virginia
- Conditions
- Older Adults (65 Years and Older)
- Interventions
- Not listed
- Lead sponsor
- Michigan State University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- East Lansing, Michigan
- Conditions
- Pharmacogenetic Testing
- Interventions
- Genecept Assay and G-DIG decision tool
- Genetic
- Lead sponsor
- Seattle Institute for Biomedical and Clinical Research
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Tacoma, Washington
- Conditions
- Fatigue, Neoplasms
- Interventions
- dexmethylphenidate(d-mph)
- Drug
- Lead sponsor
- Celgene Corporation
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Flagstaff, Arizona • Tucson, Arizona + 17 more
- Conditions
- Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
- Interventions
- Chinese herbs, cyclophosphamide, doxorubicin hydrochloride, adjuvant therapy
- Dietary Supplement · Drug · Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Acetaminophen, Drug Overdose, Acetaminophen Overdose, Acetaminophen Poisoning, Drug-induced Liver Injury, Liver Failure, Liver Toxicity
- Interventions
- Intravenous infusion of N-acetylcysteine, Intravenous infusion of Fomepizole (4-MP)
- Drug
- Lead sponsor
- Richard Dart, MD, PhD
- Other
- Eligibility
- 10 Years to 99 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Carcinoid Syndrome
- Interventions
- Telotristat etiprate, Octreotide LAR Depot, Placebo
- Drug
- Lead sponsor
- Lexicon Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 9
- States / cities
- Little Rock, Arkansas • San Francisco, California • Indianapolis, Indiana + 6 more
- Conditions
- Breast Cancer, Cardiotoxicity
- Interventions
- antihypertensive medications, Blood pressure measurement, Echocardiogram, Symptom-limited cardiopulmonary exercise test, Quality of Life Measures, Biomarkers
- Other · Diagnostic Test
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- cytarabine, deoxycytidine
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2001
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Antifungal Drug Adverse Reaction
- Interventions
- NES/EE CVR
- Drug
- Lead sponsor
- Population Council
- Other
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Springfield, Missouri
- Conditions
- Cardiac Toxicity, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- oblimersen sodium, dexrazoxane hydrochloride, doxorubicin hydrochloride, cyclophosphamide, filgrastim, laboratory biomarker analysis, pharmacological study
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Arcadia, California
- Conditions
- Ototoxicity
- Interventions
- DB-020, Placebo
- Drug
- Lead sponsor
- Decibel Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 4
- States / cities
- Miami, Florida • Kansas City, Kansas • Lake Success, New York + 1 more
- Conditions
- Adverse Drug Event
- Interventions
- Audit and feedback - letter and report
- Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- Not listed
- Enrollment
- 11,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Acute Liver Failure, Acute Liver Injury
- Interventions
- Ornithine Phenylacetate
- Drug
- Lead sponsor
- William Lee
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 11
- States / cities
- San Francisco, California • New Haven, Connecticut • Atlanta, Georgia + 8 more
- Conditions
- Cardiac Toxicity
- Interventions
- Moxifloxacin
- Drug
- Lead sponsor
- Haiyan Li
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- West Bend, Wisconsin
- Conditions
- Adverse Drug Event, Drug Drug Interaction, Pharmacogenomics, Elderly
- Interventions
- Pharmacogenomic Testing
- Other
- Lead sponsor
- Tabula Rasa HealthCare
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Drug Toxicity, Healthy
- Interventions
- acetaminophen, placebo
- Drug
- Lead sponsor
- Denver Health and Hospital Authority
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 398 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2011
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Denver, Colorado
- Conditions
- COVID, Drug Effect, Drug Interaction, Risk Reduction
- Interventions
- Not listed
- Lead sponsor
- Tabula Rasa HealthCare
- Industry
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Epilepsy
- Interventions
- Interviews and questionnaires
- Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Breast Cancer, Cognitive Symptoms, Memory Disorders
- Interventions
- Computer-based Cognitive Training
- Device
- Lead sponsor
- Posit Science Corporation
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Colorectal Cancer, Liver Metastases, Liver Metastasis Colon Cancer, Liver Injury, Sinusoidal Obstruction Syndrome, 5-Fluorouracil Toxicity, Liver Toxicity, Chemically-Induced
- Interventions
- Standard of care oxaliplatin-based chemotherapy, S-adenosylmethionine (SAMe) supplement, Surgery
- Radiation · Dietary Supplement · Procedure
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Los Angeles, California
- Conditions
- Anesthesia, Propofol Adverse Reaction, Etomidate Adverse Reaction, Anesthesia Complication, Anesthesia; Adverse Effect, Anesthesia; Reaction
- Interventions
- Admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), Admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7)
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Dallas, Texas